{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:27Z","timestamp":1786119327789,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,7,17]]},"DOI":"10.1097\/qad.0b013e32832cdc26","type":"journal-article","created":{"date-parts":[[2009,6,29]],"date-time":"2009-06-29T03:22:54Z","timestamp":1246245774000},"page":"1383-1388","source":"Crossref","is-referenced-by-count":9,"title":["Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients"],"prefix":"10.1097","volume":"23","author":[{"given":"Jean-Paul","family":"Viard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Fagard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Chaix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rouzioux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bouteloup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Bentata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie Colin","family":"de Verdi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golriz","family":"Pahlavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"L\u00e9vy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Ch\u00eane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/01.COH.0000194101.89944.a5","article-title":"Cytokine-based modulation of immune function in HIV infection","volume":"1","author":"L\u00e9vy","year":"2006","journal-title":"Curr Opin HIV AIDS"},{"key":"R2-11-20210130","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/00002030-200304110-00009","article-title":"IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients wit severe CD4 lymphopenia","volume":"17","author":"Carcelain","year":"2003","journal-title":"AIDS"},{"key":"R3-11-20210130","doi-asserted-by":"crossref","first-page":"10712","DOI":"10.1073\/pnas.162352399","article-title":"Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection","volume":"99","author":"Natarajan","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R4-11-20210130","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1172\/JCI23196","article-title":"Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients","volume":"115","author":"Kovacs","year":"2005","journal-title":"J Clin Invest"},{"key":"R5-11-20210130","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(98)07345-0","article-title":"Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomized trial","volume":"353","author":"L\u00e9vy","year":"1999","journal-title":"Lancet"},{"key":"R6-11-20210130","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1097\/00002030-200109070-00018","article-title":"Immunological and virological effects of long-term IL-2 therapy in HIV-infected patients","volume":"15","author":"Gougeon","year":"2001","journal-title":"AIDS"},{"key":"R7-11-20210130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00002030-200302140-00008","article-title":"Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomised controlled trial","volume":"17","author":"L\u00e9vy","year":"2003","journal-title":"AIDS"},{"key":"R8-11-20210130","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1097\/QAD.0b013e3282703825","article-title":"Long-terme effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048+-079 trials)","volume":"21","author":"Durier","year":"2007","journal-title":"AIDS"},{"key":"R9-11-20210130","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/archinte.167.6.597","article-title":"The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection","volume":"167","author":"Mitsuyasu","year":"2007","journal-title":"Arch Intern Med"},{"key":"R10-11-20210130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1086\/314831","article-title":"Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with <250\/microL CD4 T cells and undetectable plasma virus load","volume":"180","author":"Arn\u00f3","year":"1999","journal-title":"J Infect Dis"},{"key":"R11-11-20210130","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/318824","article-title":"Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected persons whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment","volume":"183","author":"David","year":"2001","journal-title":"J Infect Dis"},{"key":"R12-11-20210130","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1086\/342479","article-title":"Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment","volume":"186","author":"Marchetti","year":"2002","journal-title":"J Infect Dis"},{"key":"R13-11-20210130","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1097\/00002030-200210180-00007","article-title":"Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study-ANRS 082","volume":"16","author":"Katlama","year":"2002","journal-title":"AIDS"},{"key":"R14-11-20210130","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1086\/378293","article-title":"Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2","volume":"37","author":"Markowitz","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R18-11-20210130","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1086\/520087","article-title":"CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation","volume":"196","author":"Sereti","year":"2007","journal-title":"J Infect Dis"},{"key":"R19-11-20210130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1468-1293.2007.00440.x","article-title":"Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count 300 cells\/l who were assigned to 7.5 MIU interleukin-2.","volume":"8","year":"2007","journal-title":"HIV Med"},{"key":"R21-11-20210130","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1136\/jcp.2007.051953","article-title":"HIV infection and lymphoma","volume":"60","author":"Grogg","year":"2007","journal-title":"J Clin Pathol"},{"key":"R22-11-20210130","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/QAI.0b013e318190018c","article-title":"Interleukin-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patient, results from FHDH ANRS CO4","volume":"50","author":"Fontas","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R23-11-20210130","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N Engl J Med"},{"key":"R24-11-20210130","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of Enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N Engl J Med"},{"key":"R25-11-20210130","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1086\/587693","article-title":"Specific enfuvirtide-associated mutational pathways in HIV-1 gp 41 are significantly correlated with an increase in CD4+ cell count, despite virological failure","volume":"197","author":"Svicher","year":"2008","journal-title":"J Infect Dis"},{"key":"R26-11-20210130","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/135965350300800210","article-title":"Anti-HIV-1 activity of enfuvirtide (T20) by inhibition of bystander cell death","volume":"8","author":"Barretina","year":"2003","journal-title":"Antivir Ther"},{"key":"R27-11-20210130","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/01.aids.0000131350.22032.b5","article-title":"Immunological and virological study of enfuvirtide-treated HIV-positive patients","volume":"18","author":"Barretina","year":"2004","journal-title":"AIDS"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-200907170-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:59:50Z","timestamp":1786039190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200907170-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,17]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32832cdc26","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7,17]]}}}